Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Objective: To describe the implementation of nirsevimab for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease in a pediatric hospital, focusing on strategies to ensure equitable access and address logistical challenges. Additionally, we aimed to identify predictors of nirsevimab deferral among eligible infants. Patients and Methods: Our hospital implemented a universal immunization campaign to all eligible infants, including those discharged from the newborn nursery, intermediate care nursery (ICN), and neonatal intensive care unit (NICU).
View Article and Find Full Text PDFUtility of respiratory viral testing in the risk stratification of young febrile infants presenting to emergency care settings: a protocol for systematic review and meta-analysis.
BMJ Paediatr Open
October 2024
Wellcome Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Introduction: Febrile infants under 3 months of age are at risk of invasive bacterial infection (IBI). It is currently unclear if testing for respiratory viruses may have a role in IBI risk stratification. If found to be associated with the likelihood of IBI, respiratory viral point-of-care testing may improve patient and caregiver experience, reduce costs and enhance antimicrobial stewardship.
View Article and Find Full Text PDFListening to the Voice of the Patient in RSV Research.
Pediatr Infect Dis J
September 2024
Department of Pediatrics, University Medical Center Utrecht, Utrecht.
Patient and public involvement in research refers to patients or caregivers with disease experience contributing to the design, conduct or dissemination of results from research. Patient and public involvement has given rise to new fields in healthcare-oriented research and has the potential to transform infectious diseases through interventional trials. Our recommendations and best practices from years of organizing respiratory syncytial virus parent networks are provided.
View Article and Find Full Text PDFImplementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain.
Hum Vaccin Immunother
December 2024
Prevention and Health Protection Service, Ministry of Health, Murcia, Spain.
Article Synopsis
- Respiratory syncytial virus (RSV) is a major cause of respiratory infections in infants under one year, and in the 2023/2024 season, Spain initiated the use of the monoclonal antibody nirsevimab to protect this population.
- The immunization effort saw high coverage rates (91.5% for newborns during the season) and quick administration of the vaccine, with an average delay of just 27.45 days for those who initially chose not to immunize.
- The campaign was particularly effective, especially among healthy infants, leading to a lower average age of vaccination compared to those with risk conditions, thus indicating overall success in the immunization strategy in the Region of Murcia, Spain.
Viral infection and sudden non-cardiac death: A systematic review.
J Forensic Leg Med
August 2024
Faculdade de Medicina da Universidade do Porto, Portugal; Instituto Nacional de Medicina Legal e Ciências Forenses, I.P, Portugal.
Introduction: Sudden non-cardiac death (SNCD) is a clinical entity comprising deaths lacking previous clinically significant symptoms, and in which the mechanisms of death do not involve the heart. Infection is a major cause of SNCD, particularly in children, and viruses are frequently involved in the disease process. Nevertheless, SNCD of viral infectious causes remains poorly characterized.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!